ENTRY       D10440                      Drug
NAME        Lampalizumab (USAN/INN)
FORMULA     C2068H3214N546O676S13
EXACT_MASS  46929.0273
MOL_WEIGHT  46957.7444
SEQUENCE    (Heavy chain)
            EVQLVQSGPE LKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW INTYTGETTY
            ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVYYCEREG GVNNWGQGTL VTVSSASTKG
            PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
            SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THT
            (Light chain)
            DIQVTQSPSS LSASVGDRVT ITCITSTDID DDMNWYQQKP GKVPKLLISG GNTLRPGVPS
            RFSGSGSGTD FTLTISSLQP EDVATYYCLQ SDSLPYTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H142-H198, H218-L214, L23-L88, L134-L194)
  TYPE      Peptide
EFFICACY    Aging-related macular degeneration therapeutic agent
  TYPE      Monoclonal antibody
COMMENT     Treatment of geographic atrophy secondary to age-related macular degeneration
TARGET      CFD [HSA:1675] [KO:K01334]
BRITE       Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                CFD
                 D10440  Lampalizumab (USAN/INN)
DBLINKS     CAS: 1278466-20-8
            PubChem: 172232533
///
